Articles tagged "Kidney transplantation"

2019 American Transplant Congress
The Dry Weight Revealed!, What Transplanted Kidneys Teach Us about the (Dry Weight).
M. Hamid¹, S. Oyewolle-Eletu², G. Gudleski², K. Speta³, J. Kumar¹, S. Chang¹
¹Nephrology-Transplant, State University of New York at Buffalo (SUNY) Buffalo, Buffalo, NY, ²Jacob's School of Medicine, State University of New York at Buffalo (SUNY) Buffalo, Buffalo, NY, ³Nephrology-Transplant, Erie County Medical Center, Buffalo, NY
*Purpose: Volume overload in patients with ESRD/CKD V patients is associated with worse operative outcomes and potentially higher rate of delayed graft function, in addition…
2019 American Transplant Congress
Use of Eculizumab for Active Antibody-Mediated Rejection That Occurs Early Post-Kidney Transplantation: A Consecutive Series of 15 Cases
E. Tan¹, B. J. Andrew², P. G. Dean², M. F. Shaheen¹, M. D. Stegall², C. A. Schinstock²
¹Division of Transplantation Surgery, Mayo Clinic Rochester, Rochester, MN, ²The William J von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic Rochester, Rochester, MN
*Purpose: Active antibody-mediated rejection (ABMR) that occurs during the amnestic response within the first month post-transplant is a rare but devastating cause of early allograft…
2019 American Transplant Congress
Barriers to Listing for Kidney Transplantation in LMICs: A Single Center Retrospective Cohort Study in Brazil
Y. Yu¹, G. Ferreira², A. Saha¹, M. Henderson¹, D. Segev¹, J. Bastos², V. Colares², A. Massie¹
¹Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD, ²Santa Casa de Misericordia de Juiz de Fora, Juiz de Fora, Brazil
*Purpose: Incidence of end-stage renal disease (ESRD) is increasing in low- and middle-income countries (LMICs), but citizens of LMICs face barriers to transplantation that are…
2019 American Transplant Congress
Hepatitis A Hospitalizations among Kidney Transplant Recipients in the United States: A Nationwide Study
W. Cheungpasitporn¹, C. Thongprayoon², P. Ungprasert³, K. Wijarnpreecha⁴, P. T. Kroner⁴
¹Nephrology, University of Mississippi Medical Center, Jackson, MS, ²Nephrology and Hypertension, Mayo Clinic, Rochester, MN, ³Nephrology, University of Mississippi Medical Center, Bangkok, Thailand, ⁴Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL
*Purpose: Hepatitis A illness severity increases in immunosuppressed patients and one of important indicators of hepatitis A illness severity is whether patients require hospitalization. This…
2019 American Transplant Congress
Characteristics And Outcomes Of Early Onset Cancers After Kidney Transplantation
W. Lim¹, E. Au², A. Krishnan¹, G. Wong²
¹Sir Charles Gairdner Hospital, Perth, Australia, ²University of Sydney & Westmead Hospital, Sydney, Australia
*Purpose: Incident cancers developing after kidney transplantation are associated with significant morbidity and mortality and therefore age-appropriate cancer screening is recommended to identify asymptomatic cancers…
2019 American Transplant Congress
Full and Sustained Donor Hematopoietic Chimerism after an Isolated Kidney Transplantation
J. Zuber¹, O. Boyer¹, B. Neven¹, E. Six², R. Berthaud¹, M. Ould Rabah¹, S. Sobrino², C. Lagresle², I. André-Schmutz², M. Cavazzana¹, S. Blanche¹, R. Salomon¹
¹Paris Descartes University, Paris, France, ²Inserm UMRS 1163, Paris, France
*Purpose: Full donor chimerism was reported three times in the absence of myelosuppressive regimen, only after liver or multivisceral transplantation, but never after kidney transplantation.…
2019 American Transplant Congress
Bcl-2 Inhibition with Venetoclax Promotes Induction of Mixed Chimerism and Renal Allograft Tolerance without Severe Myelosuppression in Non-Human Primate
H. Sasaki¹, D. Ma¹, T. Oura¹, A. Dehnadi¹, I. Rosales², B. Cosimi¹, P. Cippa³, T. Fehr³, T. Kawai¹
¹Surgery, Massachusetts General Hospital, Boston, MA, ²Pathology, Massachusetts General Hospital, Boston, MA, ³Medicine, University of Zurich, Zurich, Switzerland
*Purpose: Specific Bcl-2 inhibition has been shown to promote mixed chimerism and skin allograft tolerance without myelosuppressive conditioning in murine models. To extend this approach…
2019 American Transplant Congress
Evaluation of the Safety and Tolerability of Clazakizumab® (Anti-IL-6 Monoclonal) as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (nct03380962)
A. A. Vo, N. Ammerman, E. Huang, A. Peng, R. Najjar, S. Sethi, S. Williamsons, C. Myers, K. Lim, J. Choi, S. C. Jordan
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Currently, there is growing interest in development of novel immune-modulatory drugs likely to improve allo-antibody reduction in transplantation. Clazakizumab (Vitaeris Inc.) is a humanized…
2019 American Transplant Congress
Impact of Immunosuppressive Drug Withdrawal on Persistent Mixed Chimerism in Recipients of HLA Haplo-Identical Kidney and Hematopoietic Cell Transplants
S. Busque, J. Scandling, R. Lowsky, J. Shizuru, E. Meyer, K. Jensen, A. Shori, R. Hoppe, E. Engleman, S. Strober
Stanford University School of Medicine, Stanford, CA
*Purpose: We assessed the impact of the hematopoietic cell dose and the immunosuppressive drug (IS) withdrawal on the persistence of mixed chimerism after combined HLA…
2019 American Transplant Congress
Kinetics of Pretransplant DSA, Post-Transplant Histology, and Graft Failure after Kidney Transplantation
A. Senev¹, E. Lerut², V. Van Sandt³, J. Callemeyn¹, M. Coemans¹, B. Sprangers², D. Kuypers², M. Emonds¹, M. Naesens²
¹Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium, ²University Hospitals Leuven, Leuven, Belgium, ³Histocompatibility and Immunogenetics Laboratory, Belgian Red Cross-Flanders, Mechelen, Belgium
*Purpose: The association between the kinetics of pretransplant DSA levels and outcome after kidney transplantation is currently not well known. In this large cohort study…